Division of Medical Biotechnology, Department of Laboratory Sciences, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.
Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Mol Biol Rep. 2019 Dec;46(6):6205-6213. doi: 10.1007/s11033-019-05059-0. Epub 2019 Sep 6.
Targeting erb-b2 receptor tyrosine kinase 2 (ERBB2) using the combination of Trastuzumab and Pertuzumab has demonstrated promising results in breast cancer therapy. It has further been revealed that interleukin-2 (IL-2) can activate Natural Killer cells (NK cells) and elevate their cytotoxic potency against tumor cells. In this study, we explored the cytotoxic effect of recombinant human IL-2 in combination with Trastuzumab and Pertuzumab on the ERBB2 positive (SK-BR-3) and negative (MDA-MB-231) breast cancer cell lines. The cytotoxicity level of IL-2 activated NK cells (approximately 75%) were significantly higher than untreated cells (approximately 55%) in the presence of Trastuzumab and Pertuzumab against SK-BR-3 cells, while no difference was observed in the case of MDA-MB-231 cells (about 15%).
使用曲妥珠单抗和帕妥珠单抗靶向 erb-b2 受体酪氨酸激酶 2（ERBB2）在乳腺癌治疗中已显示出良好的效果。进一步发现，白细胞介素-2（IL-2）可以激活自然杀伤细胞（NK 细胞），提高其对肿瘤细胞的细胞毒性。在这项研究中，我们探讨了重组人白细胞介素-2与曲妥珠单抗和帕妥珠单抗联合应用对 ERBB2 阳性（SK-BR-3）和阴性（MDA-MB-231）乳腺癌细胞系的细胞毒性作用。在存在曲妥珠单抗和帕妥珠单抗的情况下，IL-2 激活的 NK 细胞（约 75%）对 SK-BR-3 细胞的细胞毒性水平明显高于未经处理的细胞（约 55%），而在 MDA-MB-231 细胞中则没有观察到差异（约 15%）。
